AG002X6C

289499-45-2 | 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, hydrochloride (1:2)

Chemical structure of 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, hydrochloride (1:2), CAS 289499-45-2
AG002X6C
sdsSDS
sdsCOA

Price

$0.00

WARNING This product is not for human or veterinary use.
Request For Quotation
CAS Number 289499-45-2
Catalog Number AG002X6C(AGN-PC-0JPKXV)
Chemical Name 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, hydrochloride (1:2)
IUPAC Name N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide;dihydrochloride
InChI InChI=1S/C24H25ClFN5O3.2ClH/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16;;/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29);2*1H
InChI Key JZZFDCXSFTVOJY-UHFFFAOYSA-N
MDL Number MFCD09837878
Molecular Formula C24H26Cl2FN5O3
Molecular Weight 522.3993
SMILES N(c1c2c(cc(c(c2)NC(=O)C=C)OCCCN2CCOCC2)ncn1)c1cc(Cl)c(cc1)F.Cl
UNII ICJ93X8X90
Synonyms
canertinib dihydrochloride, CI 980, CI-980, PD 183805, PD-183805, PD183805, Canertinib dihydrochloride, 289499-45-2, CI-1033, Canertinib HCl, CI 1033, Canertinib (dihydrochloride), UNII-ICJ93X8X90, PD 183805, Canertinib dihydrochloride [USAN], PD-0183805, ICJ93X8X90, MFCD09954112, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide dihydrochloride, Q-101362, Q-200787, CHEMBL545315, Canertinib dihydrochloride (USAN), 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride, 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride, 2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, hydrochloride (1:2), N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride, N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride, C24H25ClFN5O3.2ClH, Canertinib HCl, Canertinib 2HCl, Canertinib.2HCL, CI-1033 dihydrochloride, Canertinib(dihydrochloride), AC1L4G5O, PD-183805 dihydrochloride, Canertinib dihydrochloride salt, SCHEMBL2052123, AOB6735, DTXSID80183143, BCP01902, KS-00000FV0, 3516AH, HY-10367A, RS0031, AKOS015924656, AC-2414, AN-6697, CS-0263, KIN0000080, AK326128, BC673861, SC-23744, SN-26606, AB1004832, LS-185636, A3276, AM20090674, FT-0724289, CI-1033, >=98% (HPLC), A19399, D03350, W-5427, Canertinib dihydrochloride; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride, N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride, N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride, Canertinib, Candesartan cilexetil, Canertinibdihydrochloride, cc-446, PD-183805, PD183805, CI1033, CI-103, CID156413, Canertinib dihydrochloride(CI 1033), 289499-45-2 (HCl salt), ACN-040200, C24-H25-Cl-F-N5-O3.2Cl-H, C420268, N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide, 267243-28-7,

Related Research Chemicals

CERTIFICATE OF ANALYSIS
Chemical Name: Batch Number:
Chemical Structure: CAS Registry No:
Product ID:
Manufacture Date:
Storage Temperature:
Formula:
Molecular Weight:
Quantity:
Analysis Data:
Test: Result:
Conclusion: The above product meets the specifications of Angene.
Analyst:Chase
Date:
Reviewed by:Jessie
Date:
Angene International Limited